January 16, 2025

With lipid nanoparticles (LNPs), PROGEN offers an alternative drug delivery tool for the gene therapy market

With lipid nanoparticles (LNPs), PROGEN offers an alternative drug delivery tool for the gene therapy market

Non-viral platform for efficient drug transfer to facilitate clinical developments

Heidelberg, 15.01.2025 – PROGEN, leading manufacturer of Adeno-Associated-Virus (AAV) analytical tools for gene therapy research and development, announces the launch of LNPs for the versatile delivery of therapeutic agents into cells.


In the past decade, PROGEN has driven progress in gene therapy by providing reliable ELISA assays for AAV vector characterization and titer determination that enable safe and reliable gene transfer. Answering the market need for a non-viral drug delivery system that overcomes common hurdles, such as nucleic acid degradation, insolubility or inefficient administration, the company is now offering customized LNP kits in addition to its comprehensive analytical AAV product range.


LNPs are composed of a blend of lipids, formulated to transport nucleic acids, proteins or other small molecules efficiently into target cells. Their versatile structure provides robust protection from degradation, ensures high cell internalization, and a rapid delivery rate of encapsulated therapeutic candidates (e.g. APIs, anionic peptides, proteins, or mRNA). The efficiency of the biocompatible, loaded nanoparticles can be monitored with real-time fluorescent imaging. By improving solubility, pharmacokinetics, pharmacodynamics and overall therapeutic activity, LNPs have been designed to accelerate clinical development and PROGEN can collaborate with CDMOs to provide GMP-manufactured formulations as a scalable platform for clinical research organizations worldwide.


“The introduction of LNPs is a significant step forward in our commitment to supporting scientists in advancing gene therapy”, says Katja Betts, CEO. “We are excited to be able to offer a non-viral kit platform for the safe and efficient delivery of various cargoes, in addition to our AAV analytical tools‘‘, adds Maik Lander, CEO.


PROGEN intends to continue driving progress in the gene therapy field with a global market value of 17.4B USD in 2023 (ExpertMarketResearch) and a projected 18% share of LNPs in 2036 (insightaceanalytics).

”Lipid nanoparticles are a safe and efficient method to deliver drugs into cells.”


About PROGEN
PROGEN is dedicated to supporting scientific discoveries and advancing research in gene therapy. Our mission is to help accelerate the development of safe, effective therapies to improve the lives of those affected by disease. With a team of experts and global partnerships, we go beyond manufacturing antibodies, proteins, and ELISA kits. We focus on understanding the needs of scientists to create high-quality, tailored solutions that address research challenges across academia, biotech, and pharma. At PROGEN, we strive to be a trusted partner, driving innovation and progress in groundbreaking research in gene therapy.

Our latest News

discover more
Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. In a mouse […]

ERC Awards Four Starting Grants to Universität Heidelberg

ERC Awards Four Starting Grants to Universität Heidelberg

European Research Council funds groundbreaking projects by early-career researchers The European Research Council is awarding four valuable grants to Heidelberg University. These ERC Starting Grants go to researchers in early stages of their career who want to carry out groundbreaking research with ERC funding. They include Dr Michael Gerlt, who will do research at the […]

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone will support the company’s growth and upscaling efforts, and provide the world’s largest HPL output, with 20,000L […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp